PD-1/PD-L1抑制剂联合化疗一线治疗晚期胆道恶性肿瘤的疗效及安全性研究

王荣 ,  周昳欣 ,  薛璟 ,  郝吉庆 ,  黄帆 ,  邢江浩

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1076 -1084.

PDF (2175KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1076 -1084. DOI: 10.12092/j.issn.1009-2501.2026.08.008

PD-1/PD-L1抑制剂联合化疗一线治疗晚期胆道恶性肿瘤的疗效及安全性研究

作者信息 +

Efficacy and safety of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of advanced biliary malignancies in the first line of chemotherapy

Author information +
文章历史 +
PDF (2226K)

摘要

目的: 探索程序性细胞死亡蛋白-1/其配体-1(programmed cell death protein-1/its ligand-1,PD-1/PD-L1)抑制剂联合化疗一线治疗晚期胆道恶性肿瘤的疗效及安全性。方法: 回顾性收集2020年8月至2022年8月安徽医科大学第一附属医院收治的33例经组织病理学确诊的晚期胆道恶性肿瘤患者,根据一线治疗中是否应用PD-1/PD-L1抑制剂分为常规化疗组和联合免疫治疗组,每2周期进行疗效评价,每周期评价安全性,主要研究终点为无进展生存期(progression-free survival,PFS),次要终点为治疗的安全性。结果: 33例患者无完全缓解(complete response,CR)病例,常规化疗组16例患者,其中部分缓解(partial response,PR)3例、疾病稳定(stable disease,SD)6例、疾病进展(progressive disease,PD)7例,客观有效率(objective response rate,ORR)为18.8%,疾病控制率(disease control rate,DCR)为56.2%。中位PFS为13.1周。联合免疫治疗组17例患者,其中PR 8例、SD 5例、PD 4例,ORR为47.1%,DCR为76.5%,中位PFS为21.9周,优于常规化疗组,且差异具有统计学意义。两组不良反应多为1-2级,可耐受,差异均无统计学意义。结论: PD-1/PD-L1抑制剂联合化疗和/或抗血管药物治疗晚期胆道恶性肿瘤疗效确切,安全性良好,PD-1/PD-L1抑制剂联合化疗治疗晚期胆道恶性肿瘤的治疗模式值得临床进一步探索。

Abstract

AIM: To explore the efficacy and safety of programmed cell death protein-1/its ligand-1 (PD-1/PD-L1) inhibitors combined with chemotherapy in the treatment of advanced biliary malignancies in the first line of chemotherapy. METHODS: A retrospective collection of 33 patients with advanced biliary malignant tumors confirmed by histopathology in the First Affiliated Hospital of Anhui Medical University from August 2020 to August 2022 were retrospectively collected, and they were divided into chemotherapy group and chemotherapy combined with PD-1/PD-L1 inhibitor group, and the efficacy was evaluated every 2 treatment cycles, and the safety was evaluated every cycle. The first outcome is PFS and the secondary endpoint is the safety of treatment. RESULTS: Among 16 patients in the chemotherapy group, there were 3 PR cases, 6 SD cases and 7 PD cases, with an ORR rate of 18.8% and a DCR rate of 56.2%. The median PFS was 13.1 weeks. Among 17 patients in the immunotherapy group, there were 8 PR cases, 5 SD cases and 4 PD cases. The ORR rate was 47.1%, the DCR rate was 76.5%, and the median PFS was 21.9 weeks, which was better than the chemotherapy alone. Most of the adverse effects in the two groups were 1-2 grade tolerable, and the difference was not statistically significant. CONCLUSION: PD-1/PD-L1 inhibitors combined with chemotherapy and/or anti-vascular drugs for advanced biliary malignancies have a definite efficacy and is safety, and the treatment with PD-1/PD-L1 inhibitors combined with chemotherapy for advanced biliary malignancies deserves further clinical exploration.

关键词

晚期胆道恶性肿瘤 / 免疫检查点抑制剂 / 化疗 / PD-1/PD-L1

Key words

advanced biliary malignancies / Immune checkpoint inhibitors / chemotherapy / PD-1/PD-L1

引用本文

引用格式 ▾
王荣,周昳欣,薛璟,郝吉庆,黄帆,邢江浩. PD-1/PD-L1抑制剂联合化疗一线治疗晚期胆道恶性肿瘤的疗效及安全性研究[J]. 中国临床药理学与治疗学, 2026, 31(8): 1076-1084 DOI:10.12092/j.issn.1009-2501.2026.08.008

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J].Ann Oncol, 2023, 34(2): 127-140.

[2]

Nwankwo EC, Guta A, Cao SS, et al. Incidence and long-term outcomes of biliary tract cancers in olmsted county, minnesota from 1976 to 2018[J].Cancers (Basel), 2024, 16(15): 2715.

[3]

郑康炼, 王晓东. 胆道恶性肿瘤系统治疗与局部治疗的现状及进展[J].临床肝胆病杂志, 2022, 38(2): 483-488.

[4]

Shroff RT, Bachini M. Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives[J].Future Oncol, 2024, 20(20): 1435-1450.

[5]

Renteria Ramirez DE, Knøfler LA, Kirkegård J, et al. Prognosis related to treatment plan in patients with biliary tract cancer: a nationwide database study[J].Cancer Epidemiol, 2024, 93: 102688.

[6]

施国明, 裴晏梓, 陆品相, 等. 胆道系统恶性肿瘤免疫检查点抑制剂治疗[J]. 临床肝胆病杂志, 2022, 38(5): 998-1001.

[7]

范瑞林, 丁宗仁, 曾永毅. 胆道恶性肿瘤的精准诊疗[J].临床肝胆病杂志, 2023, 39(9): 2025-2030.

[8]

Oh DY, He AR, Qin S, et al. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study[J].J Hepatol, 2025, 82(1): 85-94.

[9]

Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2023, 401(10391): 1853-1865.

[10]

Zhang TQ, Geng ZJ, Zuo MX, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study[J].Signal Transduct Target Ther, 2023, 8(1): 413.

[11]

Huang D, Ke L, Cui H, et al. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials[J].BMC Cancer, 2023, 23(1): 474.

[12]

Olkus A, Tomczak A, Berger AK, et al. Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data[J].Target Oncol, 2024, 19(2): 213-221.

[13]

Shroff RT, King G, Colby S, et al. SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers[J].J Clin Oncol, 2025, 43(5): 536-544.

[14]

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J].Nat Rev Drug Discov, 2019, 18(3): 197-218.

[15]

Guo J, Zhou Q, Zhou M, et al. Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: a retrospective study[J].Cancer Med, 2023, 12(22): 20699-20711.

[16]

Zhao Y, Yang M, Feng J, et al. Advances in immunotherapy for biliary tract cancers[J].Chin Med J (Engl), 2024, 137(5): 524-532.

[17]

Mahmood RD, Graham K, Gleeson J, et al. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data[J].Immunotherapy, 2023, 15(7): 517-530.

[18]

Larson AC, Knoche SM, Brumfield GL, et al. Gemcitabine modulates HLA-I regulation to improve tumor antigen presentation by pancreatic cancer cells[J].Int J Mol Sci, 2024, 25(6): 3116.

[19]

Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J].Nat Rev Clin Oncol, 2018, 15(2): 95-111.

[20]

Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer[J].Nat Genet, 2015, 47(9): 1003-1010.

[21]

Shigeta K, Datta M, Hato T, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma[J].Hepatology, 2020, 71(4): 1247-1261.

[22]

Bang YJ, Kang YK, Catenacci DV, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study[J].Gastric Cancer, 2019, 22(4): 828-837.

[23]

Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer[J].Cancer Immunol Immunother, 2019, 68(9): 1527-1535.

[24]

Li W, Wang Y, Yu Y, et al. Toripalimab in advanced biliary tract cancer[J].Innovation (Camb), 2022, 3(4): 100255.

[25]

Zou W, Wolchok JD, Chen L.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations[J].Sci Transl Med, 2016, 8(328): 328rv4.

[26]

Lin ZF, Qin LX, Chen JH.Biomarkers for response to immunotherapy in hepatobiliary malignancies[J].Hepatobiliary Pancreat Dis Int, 2022, 21(5): 413-419.

[27]

Zeng TM, Pan YF, Yuan ZG, et al. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma[J].Front Immunol, 2022, 13: 943066.

[28]

Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets[J].J Gastrointest Oncol, 2019, 10(4): 652-662.

[29]

Goeppert B, Roessler S, Renner M, et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma[J].Br J Cancer, 2019, 120(1): 109-114.

基金资助

白求恩·精医求精-晚期实体瘤科研项目(STLKY2-140)

2022年安徽省临床医学研究转化专项项目(202204295107020016)

AI Summary AI Mindmap
PDF (2175KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉